Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma

BACKGROUND: Tumor cells before and after epidermal growth-factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) therapy might display different characteristics. The aim of this study was to evaluate the influence of prior EGFR TKI therapy on the efficacy of subsequent pemetrexed plus platinum (PP)...

Descripción completa

Detalles Bibliográficos
Autores principales: Tseng, Jeng-Sen, Yang, Tsung-Ying, Chen, Kun-Chieh, Hsu, Kuo-Hsuan, Yu, Chong-Jen, Liao, Wei-Yu, Tsai, Chi-Ren, Tsai, Meen-Hsin, Yu, Sung-Liang, Su, Kang-Yi, Chen, Jeremy JW, Chen, Hsuan-Yu, Chang, Gee-Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043805/
https://www.ncbi.nlm.nih.gov/pubmed/24920920
http://dx.doi.org/10.2147/OTT.S62639

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043805/
https://www.ncbi.nlm.nih.gov/pubmed/24920920
http://dx.doi.org/10.2147/OTT.S62639

Ejemplares similares